Table 1 Summary of HR activity, as determined by ASHRA or DR-GFP assay, and sensitivity to chemotherapy or radiotherapy.

BRCA1	HR by ASHRA		HR by DR-GFP^*	Sensitivity
BRCA1	WB	qPCR	HR by DR-GFP^*	Chemotherapy^§	Radiotherapy^ǂ
WT	As wild type	As wild type	As wild type	Resistant	Resistant
I26A	Intermediate	Deleterious	Intermediate	Sensitive	Sensitive
C39Y	Deleterious	Deleterious	Deleterious	Sensitive	Sensitive
C61G	Deleterious	Deleterious	Deleterious	Sensitive	Sensitive
N-terminal deletant	Intermediate	Deleterious	Intermediate	Sensitive	ND

For evaluation of N-terminal deletion of BRCA1, ΔN was used in ASHRA, ΔN and Δ1–134 in the DR-GFP assay, and Δ1–134 in the chemosensitivity assay. *From ref.^22,29,35; ^§From 29 and 35; ^ǂFrom 25. ND, not determined.

Quick links

Search